Excellent
Fully Aligned
Patient Risk:
Low
Summary
The evaluated AI response claims (suicidal thoughts/behaviors monitoring for ≤24, pediatric safety/effectiveness not established with risks applying to pediatric patients, and tyramine/2-week post-discontinuation hypertensive crisis avoidance) are directly supported by the provided FDA label excerpts (Sections 5.1, 8.4, 5.2, 7.2) with no contradictions.
Category Scores
Accurate Statements
Antidepressant-treated patients age 24 years and younger have greater incidence of suicidal thoughts/behaviors than placebo; PARNATE should be monitored closely early in treatment and with dose changes, with consideration of changing/discontinuing regimen if emergent worsening or suicidality occurs.
Supported by FDA label excerpt Section 5.1.
Safety/effectiveness in pediatric patients are not established and risks (including suicidal thoughts/behavior) apply to pediatric patients as well.
Supported by FDA label excerpt Section 8.4.
MAOIs including PARNATE are associated with hypertensive crises triggered by high-tyramine foods/drinks; patients should avoid tyramine-containing foods/beverages during treatment and for 2 weeks after stopping.
Supported by FDA label excerpts Sections 5.2 and 7.2.
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
All evaluated safety-related claims are directly supported by the provided label excerpts and contain no contradictions or unsupported additions.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement